Munich Re’s Earnings Surge and a Trimmed Target: Two Signals, One Bullish Bet

Shares of Munich Re have clawed back from their lowest point in a year, adding 2.85% over the past week to close Monday at €486.60 on Xetra. That bounce, however, does little to erase a 14.21% slide over the past 30 days — a selloff that pushed the stock within a whisker of its 52-week trough of €467.30, touched on May 13. The rebound is tentative, and the distance to the 50-day moving average of €530.72 shows just how much ground remains to be covered.

What makes the recent weakness puzzling is the operating picture. On May 12, the reinsurer reported a first-quarter net profit of €1.71 billion, a 57% leap from the €1.094 billion posted a year earlier. The jump was fueled by a sharp drop in large-loss claims, particularly from US natural catastrophes that weighed on the prior-year quarter. The combined ratio in property-casualty reinsurance fell to 66.8%, underscoring strong underwriting profitability. Yet group revenue slipped 5.7% to €17.11 billion, almost entirely due to a weaker US dollar depressing translation effects. Insurance premiums specifically contracted to €15.0 billion from €15.8 billion, a decline management attributes to currency headwinds rather than any operational retreat.

Against this backdrop, JPMorgan’s analysts threw a curveball. Kamran Hossain lowered the price target on Munich Re from €655 to €590, a significant cut, while keeping the “Overweight” rating intact. The revision stems from reduced earnings estimates through 2028, trimmed by as much as 5%, driven by expected margin pressures in the property-casualty reinsurance segment. Hossain, however, points to Munich Re’s “Plan B” as a mitigating factor: a broader diversification into life/health reinsurance and the primary insurance subsidiary ERGO, which together should buffer the cyclical volatility of traditional reinsurance.

Should investors sell immediately? Or is it worth buying Münchener Rück?

The valuation case remains compelling even after the share price decline. The stock trades at a price-to-earnings ratio of roughly 9.3, and the expected dividend yield for the current financial year exceeds 5%. For fiscal 2025, management has proposed a dividend of €24.00 per share, with the same payout expected for 2026. The median analyst target stands at €569, while a separate survey puts the consensus average at €560 — both implying upside of around 15% to 17% from current levels. JPMorgan’s new €590 target sits comfortably above those figures.

Adding to the support is a massive share buyback program. The first tranche, worth up to €900 million, launched in mid-May and runs until August 21. The overall programme is multi-billion in size and extends through the annual general meeting in April 2027. Share cancellations will boost earnings per share for remaining holders, a clear tailwind for capital returns. Management has reiterated its full-year net profit target of €6.3 billion for 2026, leaving the summer quarter’s loss experience as the next critical test for the stock.

Technically, the shares have lifted from the 52-week low, but a sustained recovery needs to breach the moving averages overhead. The 52-week high of €605.00 remains a distant milestone. For now, the tug-of-war between robust earnings and a cautious analyst recalibration continues — with a €900 million buyback as the wild card.